ロード中...
Can formulation and drug delivery reduce attrition during drug discovery and development—review of feasibility, benefits and challenges
Drug discovery and development has become longer and costlier process. The fear of failure and stringent regulatory review process is driving pharmaceutical companies towards “me too” drugs and improved generics (505(b) (2)) fillings. The discontinuance of molecules at late stage clinical trials is...
保存先:
| 出版年: | Acta Pharm Sin B |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4590717/ https://ncbi.nlm.nih.gov/pubmed/26579359 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.apsb.2013.12.003 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|